SCHEMBL1661357

SCHEMBL1661357

COc1ccc(OC)c(C(N)CO)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA1A P35348 4/20 0.63
ADRA2A P08913 2/20 0.63
CYP2D6 P10635 2/20 0.61
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
MAPK1 P28482 1/20 0.59
BLM P54132 1/20 0.59
ADRB2 P07550 1/20 0.51
ADRB1 P08588 1/20 0.51
ADRB3 P13945 1/20 0.51
HTR2A P28223 1/20 0.50
LMNA P02545 1/20 0.49
CYP1A2 P05177 1/20 0.49
TSHR P16473 1/20 0.49
CYP2C19 P33261 1/20 0.49
ADORA3 P0DMS8 1/20 0.49
CA1 P00915 2/20 0.48
CA2 P00918 2/20 0.48
ACHE P22303 1/20 0.48
CA12 O43570 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8989278 0.87 ADRA1A (0.59) ADRA1AADRA2ACYP2D6MEN1KMT2A
SCHEMBL5663457 0.84 ADRA1A (0.60) ADRA1AADRA2ACYP2D6MEN1KMT2A
SCHEMBL11660678 0.84 ADRA1A (0.70) ADRA1AADRA2ACYP2D6MEN1KMT2A
SCHEMBL20869166 0.81 MEN1 (0.43) ADRA1AADRA2ACYP2D6MEN1KMT2A
SCHEMBL6280768 0.81 ADRA2A (0.45) ADRA1AADRA2ACYP2D6MEN1KMT2A
SCHEMBL6280754 0.81 ADRA2A (0.45) ADRA1AADRA2ACYP2D6MEN1KMT2A
SCHEMBL5368221 0.81 ADRA1A (0.56) ADRA1AADRA2ACYP2D6MEN1KMT2A
SCHEMBL4980642 0.81 ADRA1A (0.60) ADRA1AADRA2ACYP2D6MEN1KMT2A
SCHEMBL31047118 0.79 TYR (0.50) ADRA1AADRA2ACYP2D6MEN1KMT2A
SCHEMBL16953251 0.79 ADRA1A (0.58) ADRA1AADRA2ACYP2D6MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004080946-A1 PROCESS FOR THE PREPARATION OF MIDODRINE, PHARMACEUTICALLY-ACCEPTABLE SALTS THEREOF AND INTERMEDIATES APOTEX PHARMACHEM INC. (CA) 2004-09-23 WO claimed
EP-2491054-A2 SHORT CHAIN PEPTIDOMIMETICS BASED ORALLY ACTIVE GLP-1 AGONIST AND GLUCAGON RECEPTOR ANTAGONIST Cadila Healthcare Limited (IN) 2012-08-29 EP disclosed
WO-2011048614-A2 SHORT CHAIN PEPTIDOMIMETICS BASED ORALLY ACTIVE GLP-1 AGONIST AND GLUCAGON RECEPTOR ANTAGONIST CADILA HEALTHCARE LIMITED (IN) 2011-04-28 WO disclosed
WO-2004080946-A1 PROCESS FOR THE PREPARATION OF MIDODRINE, PHARMACEUTICALLY-ACCEPTABLE SALTS THEREOF AND INTERMEDIATES APOTEX PHARMACHEM INC. (CA) 2004-09-23 WO disclosed
US-20030203697-A1 Patch and production method thereof NITTO DENKO CORPORATION (JP) 2003-10-30 US disclosed
EP-0835107-A1 THE USE OF ALPHA-1C-SELECTIVE ADRENOCEPTOR AGONISTS FOR THE TREATMENT OF URINARY INCONTINENCE SYNAPTIC PHARMACEUTICAL CORPORATION (US) 1998-04-15 EP disclosed
US-5610174-A Use of α1A -selective adrenoceptor agonists for the treatment of urinary incontinence SYNAPTIC PHARMACEUTICAL CORPORATION (US) 1997-03-11 US disclosed
WO-1996038143-A1 THE USE OF ALPHA-1C-SELECTIVE ADRENOCEPTOR AGONISTS FOR THE TREATMENT OF URINARY INCONTINENCE SYNAPTIC PHARMACEUTICAL CORPORATION (US) 1996-12-05 WO disclosed